This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 51 of 170 for:    gastroenterology | Recruiting Studies | United States

The Analysis of WATS3D (Wide Area Transepithelial Sample Biopsy With 3-Dimensional Computer-Assisted Analysis) Increased Yield of Barrett's Esophagus and Esophageal Dysplasia

This study is currently recruiting participants.
See Contacts and Locations
Verified December 2016 by CDx Diagnostics
Sponsor:
Collaborators:
Rockford Gastroenterology Associates
Icahn School of Medicine at Mount Sinai
Temple University
University of Rochester
University of Kansas Medical Center
New York University Langone Medical Center
Information provided by (Responsible Party):
CDx Diagnostics
ClinicalTrials.gov Identifier:
NCT03008980
First received: December 23, 2016
Last updated: December 30, 2016
Last verified: December 2016
  Purpose
Patients will be recruited from participating institutions prior to planned routine care EGD with WATS3D brush samples and forceps biopsies. Eligibility will be reviewed and patients who are potentially eligible for the study will be approached regarding the study. If interested, participants will be consented and proceed with routine care EGD. The study coordinator or other research personnel will document information from the routine care endoscopy as part of this research study. Follow-up information collected will include WATS3D cytology and forceps biopsy pathology results from any routine care endoscopy performed during the course of participation in the study, any surgeries received and related to their condition, and any other care received as part of their condition. WATS3D samples will be sent to CDx Diagnostics for analysis.

Condition Intervention
GERD Barrett Esophagus Esophageal Dysplasia Esophagus Adenocarcinoma Other: Diagnostic Test

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional

Resource links provided by NLM:


Further study details as provided by CDx Diagnostics:

Primary Outcome Measures:
  • Outcomes of patients undergoing WATS sampling. Specifically incremental yield for Barrett's Esophagus and Esophageal Dysplasia due to WATS sampling above that noted from routine forceps biopsies in various clinical settings. [ Time Frame: up to 18 years ]

Estimated Enrollment: 75000
Study Start Date: March 2002
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Community GI Group
Diagnostic Test
Other: Diagnostic Test
Academic GI Group
Diagnostic Test
Other: Diagnostic Test
Academic Esophageal Dysplasia and Cancer
Diagnostic Test
Other: Diagnostic Test
Community Barrett's Esophagus Screening
Diagnostic Test
Other: Diagnostic Test
Community Esophageal Dysplasia
Diagnostic Test
Other: Diagnostic Test
Post-Ablation BE and Esophagus Dysplasia
Diagnostic Test
Other: Diagnostic Test
GERD, BE, and Esophageal Dysplasia
Diagnostic Test
Other: Diagnostic Test

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients with esophageal disease
Criteria

Inclusion Criteria:

  1. Both males and females at least 18 years of age undergoing EGD to evaluate signs or symptoms suggestive of upper gastrointestinal disease.
  2. Patients with known GERD undergoing a screening EGD with accompanying WATS3D biopsies and forceps biopsies.
  3. Patients with known BE undergoing a surveillance EGD with accompanying WATS3D biopsies and forceps biopsies.
  4. Patients with a known prior history (recent or remote) of dysplasia of either indefinite, low grade or high-grade, or intramucosal adenocarcinoma undergoing a surveillance EGD with accompanying WATS3D biopsies and forceps biopsies.
  5. Patients who have undergone radiofrequency ablation orcryoablation who are undergoing surveillance EGD with accompanying WATS3D biopsies and forceps biopsies will be included in the study. The results of this group of patients will be analyzed separately from patients undergoing screening and surveillance who have not been ablated.
  6. Institutional Review Board (IRB)-approved consent must be signed by patients to participate in this study.

Exclusion Criteria:

  1. Patients who on their initial evaluation have a visible highly suspicious lesion, such as a nodule or ulcer, (noted while undergoing endoscopy) that requires targeted biopsy will be excluded from the study.
  2. Patients who do not undergo both Forceps Biopsy and WATS3D biopsy of the esophagus. Subsequent endoscopic evaluation may include forceps biopsies alone, WATS3D biopsies alone, both forceps and WATS3D biopsies, or no biopsies.
  3. Patients with visible lesions that are either submucosal or covered with intact epithelium.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03008980

Contacts
Contact: Rivka Rotberg 845-368-7444 rrotberg@cdxdiagnostics.com
Contact: Stephanie Pille 845-368-7452 pstephanie@cdxdiagnostics.com

Locations
United States, Pennsylvania
Mike Smith Recruiting
Philadelphia, Pennsylvania, United States, 19140
Contact: Mike Smith, MD         
Sponsors and Collaborators
CDx Diagnostics
Rockford Gastroenterology Associates
Icahn School of Medicine at Mount Sinai
Temple University
University of Rochester
University of Kansas Medical Center
New York University Langone Medical Center
  More Information

Responsible Party: CDx Diagnostics
ClinicalTrials.gov Identifier: NCT03008980     History of Changes
Other Study ID Numbers: CDx 103
Study First Received: December 23, 2016
Last Updated: December 30, 2016

Additional relevant MeSH terms:
Adenocarcinoma
Barrett Esophagus
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Abnormalities
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases

ClinicalTrials.gov processed this record on August 22, 2017